Tag

Mflusiva

All articles tagged with #mflusiva

science2 hours ago•6 min saved

Moderna’s mRNA flu vaccine cleared for older adults, promising faster strain updates

The FDA approved Moderna’s mRNA flu vaccine, mFLUSIVA, for adults 50–64 and gave accelerated approval for adults 65+, with the potential to rapidly reformulate to match circulating influenza strains. In trials, it showed a 26.6% relative reduction in lab-confirmed flu versus standard vaccines and was generally well tolerated, though side effects were more common. Regulators in the EU, Canada, and Australia are reviewing similar uses, and a Phase IV trial is planned to assess efficacy against an enhanced 65+ vaccine. Separately, Europe has approved a combined influenza and COVID-19 mRNA vaccine (mCombriax). Experts say the technology could improve responsiveness to evolving flu strains and ease manufacturing bottlenecks, but real-world effectiveness will determine its ultimate impact.

via Nature|

#fda-approval #influenza #mflusiva

health11 hours ago•60 min saved

New Flu Shot for 50+ Promises Stronger Protection This Fall

FDA-approved Moderna’s mFlusiva, an mRNA flu vaccine, for adults 50–64 (full approval) and 65+ (accelerated approval) after trials showed about 27% higher effectiveness than the standard flu shot; the vaccine could be updated quickly to address circulating strains. It’s expected to be available this fall, though insurance coverage remains unclear. Side effects may be stronger than with traditional vaccines but are generally mild. Health experts say to get whichever flu vaccine is available to protect yourself early in the season.

via AOL.com|

#flu-vaccine #health #mflusiva

health7 days ago•3 min saved

FDA approves Moderna’s mRNA flu shot for adults 50+, after initial review reversal

The FDA has approved Moderna's mRNA seasonal flu vaccine, mFlusiva (mRNA-1010), for adults 50 and older after initially declining to review the application; Phase 3 data show the vaccine is superior to standard vaccines in preventing influenza-like illness in adults 50+, with more mild adverse events, and approvals cover ages 50-64 (and accelerated approval for those 65 and older).

via Engadget|

#adults-50 #fda #health